# RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors

> **NCT06545201** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- KRAS G12V
- T Cell Therapy

## Interventions

- **BIOLOGICAL:** RE001 T cell

## Key facts

- **NCT ID:** NCT06545201
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06545201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06545201, "RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06545201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*